Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWQ38G)

• Drug Name: ZM-241385 Drug Info
• Synonyms: ZM241385; 139180-30-6; ZM 241385; ZM-241385; CHEMBL113142; 4-(2-(7-Amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5)triazin-5-ylamino)ethyl)phenol; 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol; 4-(2-(7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol; 4-{2-[(7-Amino-2-Furan-2-Yl[1,2,4]triazolo[1,5-A][1,3,5]triazin-5-Yl)amino]ethyl}phenol; 4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol
• Cross-matching ID:
  PubChem CID: 176407
  ChEBI ID: CHEBI:92361
  CAS Number: CAS 139180-30-6
  TTD Drug ID: DMWQ38G

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[5]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[6]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[7]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[8]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[9]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[10]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[11]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[12]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[13]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[14]

Drug(s) Targeting Adenosine A2b receptor (ADORA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[15]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[15]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[16]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[11]
YT-146	DM3YVKQ	Hypertension	BA00-BA04	Phase 2	[17]
AB928	DMDOXMN	Metastatic colorectal cancer	2B91	Phase 1/2	[18]
KF-17837	DMQ6DLZ	Parkinson disease	8A00.0	Phase 1	[19]
Xanthine	DMFBOQ7	Apnea	MD11.0	Phase 1	[20]
CVT-6883	DMY84TW	Asthma	CA23	Phase 1	[21]
PBF-1129	DMOPGXM	Non-small-cell lung cancer	2C25.Y	Phase 1	[18]

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[5]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[22]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[11]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[13]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[23]
Apaxifylline	DMQMV9F	Cognitive impairment	6D71	Phase 2	[24]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[25]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[23]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[26]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[27]

Drug(s) Affected By Adenosine receptor A2a (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[28]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[29]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[30]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[31]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[32]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[33]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[35]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[31]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[31]

Drug(s) Affected By Adenosine receptor A2b (ADORA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[28]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[37]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[37]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[38]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[39]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[41]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[42]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Inhibitor	[1]
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Inhibitor	[1]
Adenosine A2b receptor (ADORA2B)	TTNE7KG	AA2BR_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Adenosine receptor A2a (ADORA2A)	OTVRBZ0I	AA2AR_HUMAN	Protein Interaction/Cellular Processes	[3]
Adenosine receptor A2b (ADORA2B)	OTCDYBBP	AA2BR_HUMAN	Protein Interaction/Cellular Processes	[4]

References

• [1] 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into ... J Med Chem. 2009 Dec 10;52(23):7640-52.
• [2] Synthesis of theophylline derivatives and study of their activity as antagonists at adenosine receptors. Bioorg Med Chem. 2010 Mar 15;18(6):2081-2088.
• [3] Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2011 Jan 27;54(2):457-71. doi: 10.1021/jm100843z. Epub 2010 Dec 27.
• [4] Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility. J Med Chem. 2011 Feb 10;54(3):877-89. doi: 10.1021/jm101349u. Epub 2011 Jan 7.
• [5] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
• [9] Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [11] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [12] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [13] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [14] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] Clinical pipeline report, company report or official report of Klus Pharma
• [17] Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
• [20] Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6.
• [21] GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
• [22] Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
• [23] Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
• [25] Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
• [26] A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
• [27] Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.
• [28] Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther. 2012 Jun 8;14(3):R138. doi: 10.1186/ar3871.
• [29] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [30] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [31] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [32] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [33] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [34] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [35] New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic Signal. 2007 Sep;3(4):339-46. doi: 10.1007/s11302-007-9068-9. Epub 2007 Sep 19.
• [36] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [37] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [38] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [39] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [40] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [41] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [42] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.